RIOCIGUAT (riociguat) by Teva is guanylate cyclase stimulators [moa]. Approved for soluble guanylate cyclase stimulator [epc].
Drug data last refreshed 1mo ago
Guanylate Cyclase Stimulators
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
Riociguat in Scleroderma Associated Digital Ulcers
Worked on RIOCIGUAT at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.